ANALYSIS OF CLINICAL EFFICACY OF A PHYTOSTIMULATHION BDNF IN THE THERAPY OF ACUTE ISCHEMIC STROKE

Abstract

The relevance of the problem of treating ischemic stroke (IS) remains due to the high mortality and disability of the population. Despite the success of reperfusion therapy, the search for effective methods of neuroprotection aimed at preserving the function of the penumbra remains a priority. The aim of the study was to evaluate the clinical efficacy and safety of the phytodrug "NeuroAiD II" (BDNF stimulator) in the complex therapy of the acute period of ischemic stroke. An analysis of data from a cohort of 85 patients was performed. The inclusion criterion was the administration of the drug within the first 24–48 hours from the onset of the disease against the background of standard basic therapy. The efficacy was assessed by the dynamics of neurological deficit (NIHSS scale), functional outcome (Rankin scale, Barthel index) and the level of brain-derived neurotrophic factor (BDNF) in blood serum on the 1st and 10th days. The results of the study demonstrated a statistically significant decrease in scores on the NIHSS scale (from 11.4±2.3 to 5.1±0.8; p<0.05) and improvement in daily activity indicators by the 10th day of treatment. The level of BDNF in the "NeuroAiD II" group increased by 45% compared to baseline data. Adverse events in the form of mild allergic reactions were registered in 3.5% of cases; no cases of serious hepatotoxicity or hemorrhagic complications were identified. A conclusion was drawn about the high clinical efficacy and safety of using the phytodrug as a neuroprotector in the acute period of IS.